Rapid communication · 28 Apr 2025
EditorialPublished 4 Jan 2018
Epigenetic altering drugs as immunotherapies.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Despite of our increasing understanding of the molecular, genetic and phenotypic progression of cancers, treatments that can effectively combat most malignant cancers remain suboptimal [1]. A major challenge with current therapies is that they focus on existing genetic abnormalities but usually become ineffectual due to cancers becoming resistant or not expressing the specific mutation. Advances in high-throughput DNA sequencing of various cancers before and after treatment and after recurrence, has provided researchers with comprehensive collections of driver and passenger mutations that can be utilised to develop novel therapies. However, these sequencing techniques can be costly and usually results in the output of large and complex datasets that require specialised knowledge of different computational analysis [2].
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cancer Immunology & Therapy.
Perspective · 28 Apr 2025
VT-Cell Exhaustion vs. Activation: Implications for Immunotherapy
Commentary · 28 Apr 2025
The Role of Costimulatory Molecules in T-Cell Activation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cancer Immunology & Therapy
- SubjectOncology & Cancer
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Rasika M. Samarasinghe”
